The FDA has approved Monjuvi (tafasitamab) for relapsed follicular lymphoma, offering hope with improved progression-free ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Follicular lymphoma is a typically slow-progressing B-cell lymphoproliferative disease that originates from transformed follicular center B cells. It is commonly marked by widespread lymph node ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Tafasitamab-cxix gains FDA approval for relapsed follicular lymphoma, showcasing significant progression-free survival benefits in combination therapy.

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous ...

Follicular lymphoma is a form of non-Hodgkin lymphoma. It’s usually slow-growing and responds well to treatment but is difficult to cure. Since it is a slow-moving cancer, doctors and patients ...

Tafasitamab was previously approved with lenalidomide for r/r diffuse large B-cell lymphoma not otherwise specified and ineligible for autologous stem cell transplant. The inMIND trial randomized ...

Company News Published 06/18/2025, 03:45 PM 0 FDA approves Monjuvi combination therapy for follicular lymphoma INCY -3.45% ...

In July 2020, Monjuvi in combination with lenalidomide received FDA approval for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise ...

Follicular lymphoma represents up to 30% of non-Hodgkin lymphoma. It has historically been challenging to treat given its tendency for frequent relapse and potential to turn into large B-cell ...